Larimar Therapeutics (LRMR) said Thursday it has begun dosing adolescents aged 12 to 17 in its pediatric pharmacokinetic, or PK, run-in study of nomlabofusp, a treatment for Friedreich's ataxia.
In the study, participants will receive weight-based doses matching the 50mg adult dose and are randomized 2:1 to receive either nomlabofusp or a placebo daily for seven days, the biotechnology company said. Adolescents who complete the PK run-in study will be eligible to join the ongoing open-label extension, or OLE study.
The OLE study assesses safety, tolerability, PK, and Tissue frataxin levels in buccal and skin cells, as well as exploratory pharmacodynamic markers and clinical outcomes during long-term subcutaneous administration of nomlabofusp.
Larimar shares were up 1% in recent after-hours activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。